10-K: Bausch Health Companies Inc. Reports 2023 Financial Results, Outlines Strategic Priorities

Bausch Health Companies Inc. released its 2023 annual report, highlighting financial performance across its segments and strategic initiatives including the potential separation of Bausch + Lomb.

Summary

• Bausch Health Companies Inc. reported total revenues of $8.757 billion for 2023, an increase from $8.124 billion in 2022 and a decrease from $8.434 billion in 2021.
• The company's operating income for 2023 was $963 million, compared to $454 million in 2022 and $450 million in 2021.
• Bausch Health experienced a net loss of $611 million in 2023, compared to a net loss of $212 million in 2022 and a net loss of $937 million in 2021.
• The company's research and development expenses were $604 million in 2023, $529 million in 2022 and $465 million in 2021.
• The report details the company's five reportable segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.
• The Salix segment, primarily consisting of U.S. GI product sales, saw revenues of $2.250 billion in 2023, with Xifaxan sales accounting for approximately 80% of this revenue.
• The International segment, excluding Bausch + Lomb and Solta Medical products, generated $1.071 billion in revenue in 2023.
• The Solta Medical segment, focused on aesthetic medical devices, reported revenues of $347 million in 2023.
• The Diversified segment, which includes neurology, dermatology, generic and dentistry products in the U.S., had revenues of $943 million in 2023.
• The Bausch + Lomb segment, encompassing global eye health products, reported revenues of $4.146 billion in 2023.
• The company continues to evaluate the potential separation of its Bausch + Lomb eye health business, subject to achieving targeted debt leverage ratios and necessary approvals.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with positive revenue growth and increased operating income, but also a significant net loss and ongoing challenges. The strategic focus and potential separation of B+L are positive, but the risks and uncertainties temper the overall sentiment.

Positives

• Total revenue increased by $633 million year-over-year, indicating growth in the company's operations.
• Operating income more than doubled from 2022 to 2023, showing improved profitability.
• The net loss decreased significantly from 2021 to 2023, suggesting a positive trend in financial performance.
• The company is actively investing in R&D, which is crucial for future growth and innovation.
• The Bausch + Lomb segment continues to be a strong performer, contributing significantly to overall revenue.
• The company is taking steps to improve patient access to its products through various programs.

Negatives

• The company still reported a net loss of $611 million in 2023, indicating ongoing financial challenges.
• The company is still subject to a number of ongoing legal proceedings, investigations and inquiries.
• The company has a significant amount of debt, which restricts the manner in which it conducts business.
• The company is dependent on a limited number of sources for certain of its finished products and raw materials.

Risks

• The company faces risks related to economic and market conditions, including inflation and potential recession.
• The B+L Separation is subject to uncertainties and may not achieve the anticipated benefits.
• The company is involved in ongoing legal proceedings and investigations, which could result in material liabilities.
• The company is dependent on third parties to meet their contractual, legal, and regulatory obligations.
• The company faces competition from generic competitors and the expiration of patent protection for key products.
• The company is subject to extensive regulation and may face challenges in complying with these regulations.
• The company is exposed to risks related to interest rates and foreign currency fluctuations.
• The company is dependent on reimbursements from governmental and other third-party payors.
• The company is subject to risks associated with the ongoing conflict between Russia and Ukraine and the ongoing conflict in the Middle East involving Israel and Hamas.
• The company is subject to risks associated with the breakdown, interruption, breach or other compromise of its information technology systems.

Future Outlook

The company continues to evaluate the potential separation of its Bausch + Lomb eye health business, subject to achieving targeted debt leverage ratios and necessary approvals. The company is also focused on core therapeutic classes and geographies that offer attractive growth opportunities and is committed to driving organic growth through internal development of new products.

Management Comments

• Management believes that each company will be better positioned to individually focus on its core businesses to drive additional growth, more effectively allocate capital and better manage its respective capital needs.
• Management believes the B+L Separation will unlock value, although there can be no assurance that it will be successful in doing so.

Industry Context

The pharmaceutical and medical device industries are highly competitive, with companies pursuing the development and acquisition of products targeting similar diseases and conditions. The company faces competition from specialty and other large pharmaceutical companies, medical device companies, biotechnology companies, OTC companies and generic manufacturers.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or competitors.
• The document does mention that the company's Days Away Rate (DAR) for employee health and safety was better than the industry average.
• The document does not provide specific financial benchmarks for comparison to other companies in the pharmaceutical or medical device industries.

Legal Proceedings

• The company is the subject of a number of ongoing legal proceedings, investigations and inquiries respecting certain of its historical distribution, marketing, pricing, disclosure and accounting practices.
• The company is involved in a number of other legal and governmental proceedings and may be involved in additional litigation in the future.
• The company is involved in a number of intellectual property litigation proceedings in the United States and Canada.

Stakeholder Impact

• Shareholders face risks related to the potential failure of the B+L Separation and the company's ongoing financial challenges.
• Employees may experience uncertainty due to management transitions and potential restructuring.
• Customers may be affected by changes in pricing and product availability.
• Suppliers and creditors face risks related to the company's financial stability and debt obligations.

Next Steps

• The company will continue to evaluate the structure of any Distribution and other related details of the B+L Separation.
• The company will continue to monitor the impacts on its businesses of the COVID-19 virus and variant and subvariant strains thereof.
• The company will continue to monitor the implementation of the two-pillar plan by the countries in which it operates, and to consider the impact of these measures.
• The company will continue to monitor these legislative developments and advocate for policies that support both innovation and access to high quality medicines for patients.

Key Dates

Keywords

Bausch Health, Bausch + Lomb, financial results, pharmaceuticals, medical devices, revenue, operating income, net loss, research and development, debt, intellectual property, generic competition, legal proceedings, regulatory risks, strategic separation